Acipimox is a niacin derivative used as a hypolipidemic agent. It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid. Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. Long-term administration is associated with reduced mortality, but unwanted effects limit its clinical use. Adverse effects include flushing (associated with Prostaglandin D2), palpitations, and GI disturbances. Flushing can be reduced by taking aspirin 20-30 min before taking Acipimox. High doses can cause disorders of liver function, impair glucose tolerance and precipitate gout.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Pravastatin | Acipimox may increase the myopathic rhabdomyolysis activities of Pravastatin. |
| Lovastatin | Acipimox may increase the myopathic rhabdomyolysis activities of Lovastatin. |
| Cerivastatin | Acipimox may increase the myopathic rhabdomyolysis activities of Cerivastatin. |
| Simvastatin | Acipimox may increase the myopathic rhabdomyolysis activities of Simvastatin. |
| Atorvastatin | Acipimox may increase the myopathic rhabdomyolysis activities of Atorvastatin. |
| Fluvastatin | Acipimox may increase the myopathic rhabdomyolysis activities of Fluvastatin. |
| Rosuvastatin | Acipimox may increase the myopathic rhabdomyolysis activities of Rosuvastatin. |
| Mevastatin | Acipimox may increase the myopathic rhabdomyolysis activities of Mevastatin. |
| Pitavastatin | Acipimox may increase the myopathic rhabdomyolysis activities of Pitavastatin. |
| Leuprolide | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Acipimox. |
| Somatotropin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Acipimox. |
| Infliximab | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Acipimox. |
| Daptomycin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Acipimox. |
| Cyclosporine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Acipimox. |
| Baclofen | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Baclofen is combined with Acipimox. |
| Sildenafil | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Acipimox. |
| Indinavir | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Indinavir is combined with Acipimox. |
| Cladribine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Acipimox. |
| Phenytoin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Phenytoin is combined with Acipimox. |
| Pamidronic acid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Acipimox. |
| Mefloquine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Mefloquine is combined with Acipimox. |
| Tacrine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Acipimox. |
| Carbimazole | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Acipimox. |
| Trimethoprim | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Acipimox. |
| Betamethasone | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Betamethasone is combined with Acipimox. |
| Montelukast | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Acipimox. |
| Zidovudine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Zidovudine is combined with Acipimox. |
| Cimetidine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Acipimox. |
| Ritonavir | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Acipimox. |
| Lercanidipine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Acipimox. |
| Ciprofloxacin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Acipimox. |
| Vincristine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Acipimox. |
| Propylthiouracil | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Acipimox. |
| Methotrexate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Methotrexate is combined with Acipimox. |
| Enalapril | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Acipimox. |
| Nizatidine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Acipimox. |
| Ivermectin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Acipimox. |
| Chloroquine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Chloroquine is combined with Acipimox. |
| Triamcinolone | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triamcinolone is combined with Acipimox. |
| Niacin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Niacin is combined with Acipimox. |
| Alendronic acid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Acipimox. |
| Clofibrate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Clofibrate is combined with Acipimox. |
| Stavudine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Acipimox. |
| Nafarelin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Acipimox. |
| Amphotericin B | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Acipimox. |
| Mycophenolate mofetil | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Mycophenolate mofetil is combined with Acipimox. |
| Lamivudine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lamivudine is combined with Acipimox. |
| Ibandronate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Acipimox. |
| Propofol | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Acipimox. |
| Terbinafine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Terbinafine is combined with Acipimox. |
| Penicillamine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Penicillamine is combined with Acipimox. |
| Ranitidine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ranitidine is combined with Acipimox. |
| Tacrolimus | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrolimus is combined with Acipimox. |
| Eprosartan | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Eprosartan is combined with Acipimox. |
| Risedronic acid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Risedronic acid is combined with Acipimox. |
| Bumetanide | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Bumetanide is combined with Acipimox. |
| Triazolam | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triazolam is combined with Acipimox. |
| Ethanol | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ethanol is combined with Acipimox. |
| Salmeterol | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Acipimox. |
| Isoniazid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Isoniazid is combined with Acipimox. |
| Methyldopa | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Methyldopa is combined with Acipimox. |
| Isotretinoin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Isotretinoin is combined with Acipimox. |
| Cytarabine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Acipimox. |
| Ganciclovir | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ganciclovir is combined with Acipimox. |
| Letrozole | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Letrozole is combined with Acipimox. |
| Sulfamethoxazole | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sulfamethoxazole is combined with Acipimox. |
| Minocycline | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Acipimox. |
| Procainamide | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procainamide is combined with Acipimox. |
| Fenofibrate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fenofibrate is combined with Acipimox. |
| Norfloxacin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Norfloxacin is combined with Acipimox. |
| Amiodarone | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amiodarone is combined with Acipimox. |
| Ofloxacin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ofloxacin is combined with Acipimox. |
| Procarbazine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procarbazine is combined with Acipimox. |
| Captopril | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Captopril is combined with Acipimox. |
| Paclitaxel | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Paclitaxel is combined with Acipimox. |
| Saquinavir | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Saquinavir is combined with Acipimox. |
| Metoclopramide | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Acipimox. |
| Dexamethasone | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Acipimox. |
| Gemfibrozil | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Gemfibrozil is combined with Acipimox. |
| Docetaxel | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Docetaxel is combined with Acipimox. |
| Bezafibrate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Bezafibrate is combined with Acipimox. |
| Colchicine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Colchicine is combined with Acipimox. |
| Fusidic acid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fusidic acid is combined with Acipimox. |
| Trabectedin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trabectedin is combined with Acipimox. |
| Raltegravir | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Raltegravir is combined with Acipimox. |
| Etofibrate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Etofibrate is combined with Acipimox. |
| Ciprofibrate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Acipimox is combined with Ciprofibrate. |
| Ubidecarenone | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Acipimox is combined with Ubidecarenone. |
| Tianeptine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Acipimox is combined with Tianeptine. |
| Mebeverine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Acipimox is combined with Mebeverine. |
| Ipecac | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Acipimox is combined with Ipecac. |
| Emetine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Acipimox is combined with Emetine. |
| Simfibrate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Acipimox is combined with Simfibrate. |
| Ronifibrate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Acipimox is combined with Ronifibrate. |
| Aluminium clofibrate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Acipimox is combined with Aluminium clofibrate. |
| Clofibride | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Acipimox is combined with Clofibride. |
| Fenofibric acid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Acipimox is combined with Fenofibric acid. |